Trial Title:
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT ID:
NCT06126276
Condition:
Malignant Female Reproductive System Neoplasm
Malignant Solid Neoplasm
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Malignant Solid Neoplasm
Conditions: Official terms:
Neoplasms
Genital Neoplasms, Female
Recurrence
Palbociclib
Maleic acid
Neratinib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo tumor biopsy
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood samples
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT scan
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
EC
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Procedure
Intervention name:
Multigated Acquisition Scan
Description:
Undergo MUGA
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
Blood Pool Scan
Other name:
Equilibrium Radionuclide Angiography
Other name:
Gated Blood Pool Imaging
Other name:
Gated Heart Pool Scan
Other name:
MUGA
Other name:
MUGA Scan
Other name:
Multi-Gated Acquisition Scan
Other name:
Radionuclide Ventriculogram Scan
Other name:
Radionuclide Ventriculography
Other name:
RNV Scan
Other name:
RNVG
Other name:
SYMA Scanning
Other name:
Synchronized Multigated Acquisition Scanning
Intervention type:
Drug
Intervention name:
Neratinib Maleate
Description:
Given PO
Arm group label:
Arm I (neratinib maleate)
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1)
Other name:
HKI-272 Maleate
Other name:
NERATINIB MALEATE ANHYDROUS
Other name:
Nerlynx
Intervention type:
Drug
Intervention name:
Palbociclib
Description:
Given PO
Arm group label:
Arm II (neratinib maleate, palbociclib)
Other name:
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
Other name:
Ibrance
Other name:
PD 0332991
Other name:
PD 332991
Other name:
PD 991
Other name:
PD-0332991
Other name:
PD0332991
Summary:
This phase II ComboMATCH treatment trial compares the effect of neratinib to the
combination of neratinib and palbociclib in treating patients with HER2 positive solid
tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors.
They work by blocking the action of an abnormal protein that signals cancer cells to
multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and
palbociclib in combination may shrink or stabilize cancers that over-express a specific
biomarker called HER2.
Detailed description:
PRIMARY OBJECTIVE:
I. To investigate the efficacy of neratinib plus palbociclib (PD-0332991) compared to
neratinib maleate (neratinib) alone in patients with HER2+ gynecologic cancers and HER2+
solid tumors by evaluating progression-free survival (PFS).
SECONDARY OBJECTIVES:
I. To investigate outcome in terms of objective response rate (ORR) by Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1.
II. To investigate clinical benefit rate (ORR + stable disease at 16 weeks). III. To
evaluate overall (OS) survival. IV. To evaluate the ORR of patients who crossed over from
neratinib monotherapy to neratinib-palbociclib combination.
V. To investigate adverse events especially grade 3 and 4 toxicities by Common
Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.
VI. Collect tissue and provide it to the ComboMATCH Registration Protocol to assess
concordance between the diagnostic tumor mutation profile generated by the Designated
Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment
circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma, as
described in ComboMATCH Registration Protocol.
EXPLORATORY TRANSLATIONAL OBJECTIVES:
I. To investigate the role of ctDNA-HER2 status at baseline and during follow up to
assess if it predicts response to therapy and disease progression and if it does
correlate with tumor tissue based HER2 status.
II. To investigate if activation of the pathways of interest (PI3K/mTOR and RB1,
CCND1-CDK4/6 CDK and RAS/RAF/MAPK) in tumor tissue as well as blood/ctDNA correlate with
response or resistance to therapy.
III. To correlate extent of HER2 amplification with response to treatment and with HER2
expression by immunohistochemistry or fluorescence in situ hybridization (FISH).
IV. To correlate the extent of HER2 amplification with HER2 expression by RNA and protein
immunohistochemistry (IHC) analyses and FISH.
V. To correlate expression of Rb1, CCND1, CCNE1, CDK4/6 protein expression with response
to treatment.
VI. Assess alteration in RB1-CDK pathway in neratinib resistant patients at time of
progression on monotherapy compared to combination neratinib-palbociclib.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive neratinib maleate orally (PO) once daily (QD) on days 1-14 of
cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then
receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat
every 28 days in the absence of disease progression or unacceptable toxicity. Patients
who experience progression may crossover to Arm II. Patients undergo echocardiogram
(ECHO) or multi-gated acquisition scan (MUGA) during screening and on study, and computed
tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples
throughout the trial. Patients may also undergo tumor biopsy during screening and on
study.
ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence
of disease progression or unacceptable toxicity. Patients then receive neratinib maleate
PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles
repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection
of blood samples throughout the trial. Patients may also undergo tumor biopsy during
screening and on study.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must have enrolled onto EAY191 and must have been given a treatment
assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable
mutation as defined in EAY191
- Patients must have a HER2 amplified solid tumor except breast cancer. Patient's
cancer must have HER2 amplification as defined with ≥ 7 copies by next generation
sequencing (NGS) testing
- Patients must have recurrent or persistent disease
- No known evidence of RB1 loss or deletion including copy number loss or deleterious
mutation
- Patients must have disease that can be safely biopsied and agree to a pre-treatment
biopsy or, if disease cannot be safely biopsied, have archival tissue available from
within 12 months prior to the date of registration on the ComboMATCH Registration
Trial (EAY191)
- Patients must have measurable disease based on RECIST 1.1. A second measurable
lesion outside of the biopsiable lesion is required
- Patients with treated brain metastases are eligible if follow up brain imaging after
central nervous system (CNS) directed therapy shows no evidence of progression for 3
months or more and patient is not on steroids and is asymptomatic
- No known leptomeningeal disease
- Patients may have received up to 5 prior lines of systemic therapy
- Prior therapy with trastuzumab or pertuzumab, either alone or in combination, is
allowed
- One prior line of anti-HER2 therapy is allowed except tyrosine kinase inhibitors
(TKI) such as neratinib or tucatinib or antibody drug conjugates (ADC) such as
DS8201a or T-DM1
- No prior therapy with CDK4/6 inhibition
- No cancer directed therapy within 3 weeks prior to registration. For oral therapy,
the washout can be reduced to greater than or equal to 5 half lives of the drug
- Age ≥ 18
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
- Not pregnant and not nursing
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve
hemoglobin (Hgb) ≥ 9 g/dl is acceptable)
- Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula
- Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN) (patients
with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be
enrolled)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x
institutional upper limit of normal (ULN)
- Patients with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trial, patients should be class 2B or better
- No active infection requiring parenteral antibiotics
- No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not
diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or
need for drainage nasogastric or gastrostomy tube
- No current evidence of malabsorption or chronic diarrhea or any other significant
gastro-intestinal disease (e.g gastrectomy, ileal bypass, Crohn's disease,
gastroparesis), associated with moderate to severe diarrhea (grade 2 or more) or
inability to tolerate oral therapy
- No lung disease causing dyspnea at rest
- No interstitial lung disease with ongoing signs and symptoms at the time of
registration
- No history of allergic reaction to the study agents, compound of similar chemical or
biologic composition of the study agents or any of their excipients
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
205-934-0220
Email:
tmyrick@uab.edu
Investigator:
Last name:
Rebecca C. Arend
Email:
Principal Investigator
Facility:
Name:
University of South Alabama Mitchell Cancer Institute
Address:
City:
Mobile
Zip:
36688
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
251-445-9870
Email:
pfrancisco@usouthal.edu
Investigator:
Last name:
Ahmed Abdalla
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Boise
Address:
City:
Boise
Zip:
83712
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Fruitland
Address:
City:
Fruitland
Zip:
83619
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-864-5204
Investigator:
Last name:
Thomas E. Lad
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Maria T. Grosse-Perdekamp
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Maria T. Grosse-Perdekamp
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Maria T. Grosse-Perdekamp
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Memorial Medical Center
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Maria T. Grosse-Perdekamp
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-987-3005
Investigator:
Last name:
Sarah J. Sinclair
Email:
Principal Investigator
Facility:
Name:
University of Maryland/Greenebaum Cancer Center
Address:
City:
Baltimore
Zip:
21201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-888-8823
Investigator:
Last name:
Ranee Mehra
Email:
Principal Investigator
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-411-1222
Investigator:
Last name:
Sarah Shin
Email:
Principal Investigator
Facility:
Name:
UPMC Western Maryland
Address:
City:
Cumberland
Zip:
21502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
240-964-1400
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Dearborn Hospital
Address:
City:
Dearborn
Zip:
48124
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
OSF Saint Francis Hospital and Medical Group
Address:
City:
Escanaba
Zip:
49829
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Corewell Health Farmington Hills Hospital
Address:
City:
Farmington Hills
Zip:
48336
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health William Beaumont University Hospital
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Beaumont Troy Hospital
Address:
City:
Troy
Zip:
48085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Saint John's Hospital - Healtheast
Address:
City:
Maplewood
Zip:
55109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Essentia Health Sandstone
Address:
City:
Sandstone
Zip:
55072
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kalispell Regional Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Jersey City Medical Center
Address:
City:
Jersey City
Zip:
07302
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-339-5294
Email:
Roster@nrgoncology.org
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Monmouth Medical Center Southern Campus
Address:
City:
Lakewood
Zip:
08701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-923-6564
Email:
mary.danish@rwjbh.org
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Monmouth Medical Center
Address:
City:
Long Branch
Zip:
07740
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-923-6564
Email:
mary.danish@rwjbh.org
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Rutgers Cancer Institute of New Jersey
Address:
City:
New Brunswick
Zip:
08903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-235-7356
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Toms River
Zip:
08755
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-557-8294
Email:
Lennette.Gonzales@rwjbh.org
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Roswell Park Cancer Institute
Address:
City:
Buffalo
Zip:
14263
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-767-9355
Email:
askroswell@roswellpark.org
Investigator:
Last name:
Ellis G. Levine
Email:
Principal Investigator
Facility:
Name:
State University of New York Upstate Medical University
Address:
City:
Syracuse
Zip:
13210
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
315-464-5476
Investigator:
Last name:
Mary J. Cunningham
Email:
Principal Investigator
Facility:
Name:
Southeastern Medical Oncology Center-Clinton
Address:
City:
Clinton
Zip:
28328
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
919-587-9084
Email:
jfields@cancersmoc.com
Investigator:
Last name:
Samer S. Kasbari
Email:
Principal Investigator
Facility:
Name:
Duke University Medical Center
Address:
City:
Durham
Zip:
27710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-275-3853
Investigator:
Last name:
Angeles A. Secord
Email:
Principal Investigator
Facility:
Name:
Southeastern Medical Oncology Center-Goldsboro
Address:
City:
Goldsboro
Zip:
27534
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
919-587-9084
Email:
jfields@cancersmoc.com
Investigator:
Last name:
Samer S. Kasbari
Email:
Principal Investigator
Facility:
Name:
Southeastern Medical Oncology Center-Jacksonville
Address:
City:
Jacksonville
Zip:
28546
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
910-587-9084
Email:
jfields@cancersmoc.com
Investigator:
Last name:
Samer S. Kasbari
Email:
Principal Investigator
Facility:
Name:
Duke Women's Cancer Care Raleigh
Address:
City:
Raleigh
Zip:
27607
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
919-785-4878
Investigator:
Last name:
Angeles A. Secord
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital South
Address:
City:
Centerville
Zip:
45459
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Premier Blood and Cancer Center
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-276-8320
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital North
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Atrium Medical Center-Middletown Regional Hospital
Address:
City:
Franklin
Zip:
45005-1066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Cancer Care and Infusion
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-569-7515
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Upper Valley Medical Center
Address:
City:
Troy
Zip:
45373
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Sagila George
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
UPMC Altoona
Address:
City:
Altoona
Zip:
16601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-339-5294
Email:
Roster@nrgoncology.org
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center Erie
Address:
City:
Erie
Zip:
16505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Cancer Centers - Arnold Palmer Pavilion
Address:
City:
Greensburg
Zip:
15601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
724-838-1900
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Address:
City:
Mechanicsburg
Zip:
17050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center - Monroeville
Address:
City:
Monroeville
Zip:
15146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Thomas Jefferson University Hospital
Address:
City:
Philadelphia
Zip:
19107
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Mitchell I. Edelson
Email:
Principal Investigator
Facility:
Name:
University of Pittsburgh Cancer Institute (UPCI)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-647-8073
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC-Passavant Hospital
Address:
City:
Pittsburgh
Zip:
15237
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-367-6454
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Asplundh Cancer Pavilion
Address:
City:
Willow Grove
Zip:
19090
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Mitchell I. Edelson
Email:
Principal Investigator
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sarina A. Piha-Paul
Email:
Principal Investigator
Facility:
Name:
University of Virginia Cancer Center
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
434-243-6303
Email:
uvacancertrials@hscmail.mcc.virginia.edu
Investigator:
Last name:
Matthew J. Reilley
Email:
Principal Investigator
Facility:
Name:
Inova Schar Cancer Institute
Address:
City:
Fairfax
Zip:
22031
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-720-5210
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Inova Fairfax Hospital
Address:
City:
Falls Church
Zip:
22042
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-208-6650
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Marshfield Medical Center-EC Cancer Center
Address:
City:
Eau Claire
Zip:
54701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-782-8581
Email:
oncology.clinical.trials@marshfieldresearch.org
Investigator:
Last name:
Adedayo A. Onitilo
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center Green Bay
Address:
City:
Green Bay
Zip:
54301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Saint Mary's
Address:
City:
Green Bay
Zip:
54303
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
Collin D. Driscoll
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Oconto Falls
Address:
City:
Oconto Falls
Zip:
54154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Marshfield Medical Center-River Region at Stevens Point
Address:
City:
Stevens Point
Zip:
54482
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-782-8581
Email:
oncology.clinical.trials@marshfieldresearch.org
Investigator:
Last name:
Adedayo A. Onitilo
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Address:
City:
Sturgeon Bay
Zip:
54235-1495
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Marshfield Medical Center - Weston
Address:
City:
Weston
Zip:
54476
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-782-8581
Email:
oncology.clinical.trials@marshfieldresearch.org
Investigator:
Last name:
Adedayo A. Onitilo
Email:
Principal Investigator
Start date:
May 7, 2024
Completion date:
April 30, 2025
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06126276
